Surinabant, a selective cannabinoid receptor type 1 antagonist, inhibits Δ(9)-tetrahydrocannabinol-induced central nervous system and heart rate effects in humans

AIM: Cannabinoid receptor type 1 (CB(1)) antagonists have been developed for the treatment of obesity and associated risk factors. Surinabant is a high affinity CB(1) antagonist in vitro. The aim of this study was to assess the magnitude of inhibition by surinabant of CNS effects and heart rate indu...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Klumpers, Linda E, Roy, Christine, Ferron, Geraldine, Turpault, Sandrine, Poitiers, Franck, Pinquier, Jean-Louis, van Hasselt, Johan G C, Zuurman, Lineke, Erwich, Frank A S, van Gerven, Joop M A
Formato: Artigo
Idioma:Inglês
Publicado em: Blackwell Science Inc 2013
Assuntos:
Clinical Trials
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3703229/
https://ncbi.nlm.nih.gov/pubmed/23278647
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.12071
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados